Pharma Foods International Co., Ltd.
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending July 2026 (Japanese GAAP)
Consolidated results for the third quarter of the fiscal year ending July 2026: net sales of 48,455 million yen (up 3.7% year over year), operating loss of 1,430 million yen, ordinary loss of 1,545 million yen, and net loss attributable to owners of the parent of 1,061 million yen. Full-year forecast unchanged. Initiatives for creating new value, new products, and overseas expansion are being advanced. R&D expenses are 1,166 million yen, advertising and promotional expenses are 30,061 million yen.
Key Figures
- Sales: 48,555 million yen
- Operating loss: △1,430 million yen
- Ordinary loss: △1,545 million yen
- Net loss attributable to owners of the parent: △1,061 million yen
- R&D expenses: 1,116 million yen
AI要約
Business Overview
PharmaFoods is advancing new value creation based on Mid-Term Management Plan 2026. Strengthening R&D including the development of new electrode materials following the eggshell membrane material "ovoveil." In the field of drug discovery, CasMab antibodies have been licensed from Tohoku University, and Kadashiru (Kadasiru) treatment development is progressing. Expansion of sales channels centered in North America and preparation for GRAS certification are ongoing. Although sales are increasing due to new products and channels, operating and ordinary profits remain negative during the period. Full-year forecast unchanged.
Trends by Segment and Financial Impact
Biomedicals: sales of 230 million yen, segment loss of 473 million yen. BtoB: sales of 5,560 million yen, segment income of 858 million yen. BtoC: sales of 42,734 million yen, segment loss of 342 million yen. In total, advertising and promotional expenses and new product launches press margins, while brand strengthening such as the Newmo series sustains sales growth. Cash and cash equivalents are 9,057 million yen (against the previous fiscal year end).
営業損失推移
セグメント別売上高
セグメント別利益
通期予想と実績
PharmaFoods Co., Ltd.
Company overview · Stock price · Financial data · All IR
